Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401293 | 0.84 | CYP1A2 (0.48) | ALDH1A1KDM4ESMN1; SMN2CYP1A2LMNA | |
| SCHEMBL28506559 | 0.81 | CYP1A2 (0.47) | ALDH1A1KDM4ESMN1; SMN2CYP1A2LMNA | |
| SCHEMBL2339978 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KDM4ESMN1; SMN2CYP1A2LMNA | |
| SCHEMBL3109540 | 0.77 | ALDH1A1 (0.42) | ALDH1A1KDM4ESMN1; SMN2CYP1A2LMNA | |
| SCHEMBL105629 | 0.76 | LMNA (0.55) | ALDH1A1KDM4ESMN1; SMN2CYP1A2LMNA | |
| SCHEMBL29693683 | 0.76 | LMNA (0.55) | ALDH1A1KDM4ESMN1; SMN2CYP1A2LMNA | |
| SCHEMBL4570474 | 0.76 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2CYP1A2LMNA | |
| SCHEMBL30318701 | 0.76 | PDE2A (0.52) | ALDH1A1KDM4ESMN1; SMN2CYP1A2LMNA | |
| SCHEMBL10241852 | 0.76 | PDE2A (0.52) | ALDH1A1KDM4ESMN1; SMN2CYP1A2LMNA | |
| SCHEMBL27519654 | 0.76 | SMN1; SMN2 (0.42) | ALDH1A1KDM4ESMN1; SMN2CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | ALDH1A1 1175/4885KDM4E 1004/4885SMN1; SMN2 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.